Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

Denis MG, Bennouna J

Cancer Management and Research 2020, 12:12593-12602

Published Date: 8 December 2020